1-3 of 3
Daniel F Boyer, MD
Close
Sort by
Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3191.
https://doi.org/10.1182/blood-2019-132204
Published: 2019
Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Joseph G. Jurcic, MD, Azra Raza, MD, George Vlad, PhD, Eytan M. Stein, MD, Mikhail Roshal, MDPhD, Dale L. Bixby, Daniel F. Boyer, MD PhD, Carlos Enrique Vigil, MD, Sergei Syrbu, MD PhD, Mikkael A. Sekeres, MD MS, Heesun J. Rogers, MD PhD, David A. Rizzieri, MD, Anand Shreeram Lagoo, MD PhD, Gail J. Roboz, MD, Robert L. Redner, MD, David P. Steensma, MD, Rachel J. Cook, MD, Tamara Moyo, MD PhD, Michael McKeown, PhD, Nigel J. Waters, PhD, Kristin Stephens, Angela Volkert, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2633.
https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633
Published: 2017
Journal Articles

The Absolute Lymphocyte to Monocyte Ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large B-Cell Lymphoma

Sumana Devata, MD, Nicholas Herrman, Robert Briski, Farahk Keyoumarsi, Daniel F Boyer, MD, Megan S Lim, MD PhD, Nathanael G. Bailey, MD, Ryan A. Wilcox, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1646.
https://doi.org/10.1182/blood.V124.21.1646.1646
Published: 2014